Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 713-720 , August 2008

Autoradiographic and small-animal PET comparisons between 18F-FMISO, 18F-FDG, 18F-FLT and the hypoxic selective 64Cu-ATSM in a rodent model of cancer

  • Carmen S. Dence
    • ,
  • Datta E. Ponde
    • ,
  • Michael J. Welch
    • ,
  • Jason S. Lewis

      Affiliations

    • Corresponding Author InformationCorresponding author. Mallinckrodt Institute of Radiology, The Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO 63110, USA. Department of Radiology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA. Tel.: +1 646 888 3038; fax: +1 646 422 0408.

Received 4 April 2008 ,Revised 2 June 2008 ,Accepted 5 June 2008.

References 

  1. Tatum JL, Kelloff GJ, Gillies RJ, Arbeit JM, Brown JM, Chao KSC, et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol. 2006;82:699–757
  2. Brown JM. The hypoxic cell: a target for selective cancer therapy — Eighteenth Bruce F. Cain Memorial Award Lecture. Cancer Res. 1999;59:5863–5870
  3. Graeber TG, Osmanian C, Jacks T, Housman DE, Koch CJ, Lowe SW, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature (Lond). 1996;379:88–91
  4. Höckel M, Schlenger K, Aral B, Mitze M, Schäffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996;56:4509–4515
  5. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond). 1992;359:843–845
  6. Vavere AL, Lewis JS. Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. Dalton Trans. 2007;43:4893–4902
  7. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–1160
  8. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM. J Nucl Med. 2008;49:201–205
  9. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response — a preliminary report. Int J Radiat Biol Phys. 2003;55:1233–1238
  10. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging. 2003;30:844–850
  11. Dietz DW, Dehdashti FD, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rec. 2008;[in press]
  12. Rajendran JG, Mankoff DA, O'Sullivan F, Peterson LM, Schwartz DL, Conrad EU, et al. Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res. 2004;10:2245–2252
  13. Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J, et al. Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med. 1992;33:325–329
  14. Vesselle H, Schmidt RA, Pugsley JM, Li M, Kohlmyer SG, Vallières E, et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. Clin Cancer Res. 2000;6:3837–3844
  15. Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44:1426–1431
  16. McCarthy TJ, Dence CS, Welch MJ. Application of microwave heating to the synthesis of [18F]fluoromisonidazole. Appl Radiat Isot. 1993;44:1129–1132
  17. Machulla HJ, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson JR. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT). J Radioanal Nucl Chem. 2000;243:843–846
  18. Tai YC, Ruangma A, Rowland D, Siegel S, Newport DF, Chow PL, et al. Performance evaluation of the microPET focus: a third-generation microPET scanner dedicated to animal imaging. J Nucl Med. 2005;46:455–463
  19. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995;22:265–280
  20. Rajendran JG, Wilson DC, Conrad EU, Peterson LM, Bruckner JD, Rasey JS, et al. [18F]FMISO and [18F]FDG PET imaging in soft tissue sarcomas: correlation of hypoxia, metabolism and VEGF expression. Eur J Nucl Med Mol Imaging. 2003;30:695–704
  21. Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC. Cell line dependent differences in uptake and retention of the hypoxia selective nuclear imaging agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM). Nucl Med Biol. 2005;32:623–630
  22. O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, pO2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–1502
  23. Vavere AL, Lewis JS. Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. Nucl Med Biol. 2008;35:273–279
  24. Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2006;47:989–998
  25. Obata A, Yoshimoto M, Kasamatsu S, Naiki H, Takamatsu S, Kashikura K, et al. Intra-tumoral distribution of 64Cu-ATSM: a comparison study with FDG. Nucl Med Biol. 2003;30:529–534
  26. Tanaka T, Furukawa T, Fujieda S, Kasamatsu S, Yonekura Y, Fujibayashi Y. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models. Nucl Med Biol. 2006;33:743–750
  27. Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Lawhorn-Crews JM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nature Med. 1998;4:1334–1336
  28. Shields AF, Grierson JR, Stayanoff JC, Lawhorn-Crews JM, Obradovich J, Muzik O, et al. [F-18] FLT can be used to image cell proliferation in vivo. J Nucl Med. 1998;39:228p
  29. Kennedy AS, Raleigh JA, Perez GM, Calkins DP, Thrall DE, Novotny DB, et al. Proliferation and hypoxia in human squamous cell carcinoma of the cervix: first report of combined immunohistochemical assays. Int J Radiat Oncol Biol Phys. 1997;37:897–905
  30. Cherk MH, Foo SS, Poon AMT, Knight SR, Murone C, Papenfuss AT, et al. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-fluoromisonidazole and 18F-FDG PET. J Nucl Med. 2006;47:1921–1926
  31. Freyer JP. Rates of oxygen consumption for proliferating and quiescent cells isolated from multicellular tumor spheroids. Adv Exp Med Biol. 1994;345:335–342
  32. Freyer JP, Sutherland RM. A reduction in the in situ rates of oxygen and glucose consumption of cells in EMT6/Ro spheroids during growth. J Cell Physiol. 1985;124:516–524
  33. Li CY, Shan S, Huang Q, Braun RD, Lanzen J, Hu K, et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Institute. 2000;92:143–147

PII: S0969-8051(08)00139-X

doi: 10.1016/j.nucmedbio.2008.06.001

Nuclear Medicine and Biology
Volume 35, Issue 6 , Pages 713-720 , August 2008

Article Tools

* Image Usage & Resolution